Literature DB >> 30614492

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay.

Yukitomo Arao1, Kenneth S Korach2.   

Abstract

Estrogen receptor alpha (ERα) is an estrogenic ligand-dependent transcription regulator. The sequence of ERα protein is highly conserved among species. It has been thought that the function of human and mouse ERαs is identical. We demonstrate the differential 4-hydroxy-tamoxifen (4OHT) effect on mouse and human ERα ligand-binding domain (LBD) dimerization activity using the mammalian two-hybrid (M2H) assay. The M2H assay can demonstrate the efficiency of LBD homodimerization activity in mammalian cells, utilizing the transfection of two protein expression plasmids (GAL4 DNA-binding domain [DBD] fusion LBD and VP16 transactivation domain [VP16AD] fusion LBD) and a GAL4-responsive element (GAL4RE) fused luciferase reporter plasmid. When the GAL4DBD fusion LBD and the VP16AD fusion LBD make a dimer in the cells, this protein complex binds to the GAL4RE and, then, activates a luciferase gene expression through the VP16AD dependent transcription activity. The 4OHT-mediated luciferase activation is higher in the HepG2 cells that were transfected with the mouse ERα LBD fusion protein expression plasmids than in the human ERα LBD fusion protein expression plasmid transfected cells. This result suggests that the efficacy of the 4OHT-dependent mouse ERα LBD homodimerization activity is higher than human ERα LBD. In general, the utilization of the M2H assay is not ideal for the evaluation of nuclear receptor LBD dimerization activity, because agonistic ligands enhance the basal level of the LBD activity and that impedes the detection of LBD dimerization activity. We found that 4OHT does not enhance ERα LBD basal activity. That is a key factor for being able to determine and detect the 4OHT-dependent LBD dimerization activity for successfully using the M2H assay. ERα LBD-based M2H assays may be applied to study the partial agonist activity of selective estrogen receptor modulators (e.g., 4OHT) in various mammalian cell types.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30614492      PMCID: PMC6953383          DOI: 10.3791/58758

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  10 in total

1.  Molecular basis of agonism and antagonism in the oestrogen receptor.

Authors:  A M Brzozowski; A C Pike; Z Dauter; R E Hubbard; T Bonn; O Engström; L Ohman; G L Greene; J A Gustafsson; M Carlquist
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

2.  Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions.

Authors:  Akiko Koide; Changqing Zhao; Misuzu Naganuma; Judith Abrams; Sarah Deighton-Collins; Debra F Skafar; Shohei Koide
Journal:  Mol Endocrinol       Date:  2006-12-21

3.  Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta.

Authors:  C y Chang; J D Norris; H Grøn; L A Paige; P T Hamilton; D J Kenan; D Fowlkes; D P McDonnell
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

4.  Transactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating Element.

Authors:  Yukitomo Arao; Laurel A Coons; William J Zuercher; Kenneth S Korach
Journal:  J Biol Chem       Date:  2015-05-31       Impact factor: 5.157

5.  The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.

Authors:  M M Montano; V Müller; A Trobaugh; B S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  1995-07

6.  Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists.

Authors:  Huey-Jing Huang; John D Norris; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2002-08

7.  The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization.

Authors:  Jun Yang; David W Singleton; Elizabeth A Shaughnessy; Sohaib A Khan
Journal:  Mol Cell Endocrinol       Date:  2008-08-13       Impact factor: 4.102

8.  The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Authors:  A K Shiau; D Barstad; P M Loria; L Cheng; P J Kushner; D A Agard; G L Greene
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

9.  Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.

Authors:  Yukitomo Arao; Katherine J Hamilton; Laurel A Coons; Kenneth S Korach
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

10.  The F domain of estrogen receptor α is involved in species-specific, tamoxifen-mediated transactivation.

Authors:  Yukitomo Arao; Kenneth S Korach
Journal:  J Biol Chem       Date:  2018-04-09       Impact factor: 5.157

  10 in total
  2 in total

1.  Lavender Products Associated With Premature Thelarche and Prepubertal Gynecomastia: Case Reports and Endocrine-Disrupting Chemical Activities.

Authors:  J Tyler Ramsey; Yin Li; Yukitomo Arao; Ajanta Naidu; Laurel A Coons; Alejandro Diaz; Kenneth S Korach
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

Review 2.  The physiological role of estrogen receptor functional domains.

Authors:  Yukitomo Arao; Kenneth S Korach
Journal:  Essays Biochem       Date:  2021-12-17       Impact factor: 8.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.